New Program Director/Principal Investigator: David C. Brousseau, MD, MS
(Effective May 1, 2023)
Dr. David Brousseau is the Chair of Pediatrics at Nemours Children’s Health, Delaware, and the Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Brousseau is a graduate of the University of Virginia medical school. He completed his pediatric residency at the University of Colorado Health Sciences Center and his fellowship in Pediatric Emergency Medicine and Masters in Epidemiology at Brown University/Hasbro Children’s Hospital. Prior to joining Nemours Children’s Health as Chair, Dr. Brousseau was the Section Chief of Pediatric Emergency Medicine at Medical College of Wisconsin/Children’s Wisconsin.
Dr. Brousseau’s academic focus centers on the care of people with sickle cell disease (SCD). He has had continuous federal funding for almost two decades, including sickle cell randomized clinical trials and hybrid-implementation trials. He is currently the study PI on an NHLBI U01 hybrid effectiveness-implementation trial to improve guideline adherence for the care of children presenting to the ED with a painful crisis related to their SCD. Dr. Brousseau is the Chair-elect of the American College of Emergency Physician’s Emergency Department Sickle Cell Care Coalition (EDSC3), whose goal is to improve the care of children with SCD across academic and community emergency departments, both pediatric and general. In addition to his sickle cell work, Dr. Brousseau has been an active member of the Pediatric Emergency Care Applied Research Network (PECARN) including more than a decade as a member of the steering committee and two terms as Chair of the Feasibility and Budget subcommittee. He has over 110 publications, including first author publications in JAMA and Blood.
Dr. Brousseau also has an established track record of mentorship, including serving as the primary mentor on an NHLBI K23 and serving as the scientific advisor for an NHLBI funded UG3/UH3 for an interventional clinical trial for sickle cell pain. He has mentored many students, trainees and faculty to publications and funding and is excited to serve as the PI of the SCD COBRE award.
Complete List of Published Work in MyBibliography:
Previous Program Director/Principal Investigator: Edward A. Kolb, M.D.
(August 6, 2021 through April 30, 2023)
Dr. Kolb is a Board-certified Pediatric Hematologist/Oncologist who serves as Division Chief of Hematology and Oncology at Nemours Children’s Health, Delaware Valley. Dr. Kolb is the founding Director of the Nemours Center for Cancer and Blood Disorders (NCCBD), Vice Chair for Research for the Department of Pediatrics and Professor of Pediatrics at Sidney Kimmel Medical College, Thomas Jefferson University. Dr. Kolb received his medical degree from Jefferson Medical College and completed his residency at St. Christopher’s Hospital for Children in Philadelphia and his clinical and research fellowship at Memorial Sloan Kettering Cancer Center in NY.
Dr. Kolb played a key role for obtaining the funding of the Center of Biomedical Research Excellence (COBRE) Phase I Program from the National Institute of General Medical Sciences (NIGMS) of National institute of Health (NIH). The Phase I titled the Delaware Comprehensive Sickle Cell Research Center, in which he served as the Director of Clinical Data and Management Core. Dr. Kolb continued his leadership of the Program and secured a 5-year $10.5 million funding for COBRE Phase II.
Dr. Kolb has led several large, multi-site research consortiums, and is also PI of the Nemours NCI Community Oncology Research Program (NCORP), one of only two pediatric NCORPs in the country. Dr. Kolb co-chairs the Data and Safety Monitoring Board (DSMB) for the National Heart Lung and Blood Institute Clinical Trials Network (overseeing national sickle cell trials) and Chairs the DSMB for Nationwide Children’s Hospital, Division of Pediatric Hematology and Oncology. Dr. Kolb has had continuous funding from the NCI as a founding member of the Pediatric Preclinical Testing Program. He has participated and led the translation of preclinical safety and efficacy data into first-in-child clinical testing on numerous occasions and is familiar with all regulatory and sponsor requirements. He received a numerous awards and honors and was recently honored for Lifetime Achievement Received Prestigious Award From the Leukemia & Lymphoma Society in July 2021.
As COBRE Phase II PI, Dr. Kolb has also proposed to build a multidisciplinary and systematic approach to study the influence of stigma and racism within communities and the health care system on the efficacy of both routine health maintenance and targeted interventions in patients with sickle cell disease. He will develop a multidisciplinary Center that will strengthen early career investigator mentoring while further advancing biomedical research infrastructure for sickle cell disease research.